Everolimus shoots two very different birds with one stone; cancer cells and coronary stents

Everolimus shoots two very different birds with one stone; cancer cells and coronary stents

In 2009 a new anti-cancer drug, Everolimus, was approved in the US and Europe specifically for use in patients with advanced kidney cancer who were unresponsive to the standard chemotherapy regimen. As a kinase inhibitor, Everolimus effectively inhibits cancer cells from dividing. Since then, the use of Everolimus has extended to treatment of subependymal giant cell astrocytoma, pancreatic neuroendocrine tumors and other neoplasms. It has also gained acceptance as an orally administered drug to prevent transplant rejection. Evidence for this indication has been presented by Dr. Ron Shapiro wherein high-dose Everolimus improved graft survival in renal transplantation.

everolimusRecently, other applications for Everolimus have entered the world of interventional cardiology in the form of additives in coronary artery stents. Data from the SPIRIT III trial, published on January 2011, found that Everolimus-eluting stents were superior in terms of safety and efficacy compared to first-generation drug-eluting stents. Everolimus is now currently used in the popular XIENCE V® and XIENCE nano™ drug-eluting stents. Furthermore, the PLATINUM trial presented during the American College of Cardiology 2011 Scientific Sessions, using platinum as the new alloy base for the stent, added more evidence favoring the use of Everolimus in stents even when using non-chromium-cobalt based stents.

From cancer to interventional cardiology, the efficacy of Everolimus has been established. Since this drug was able to find use in two very different fields of medicine, the potential use of  Everolimus for other indications does not seem like a farfetched idea at all.

LGM Pharma prides itself in its role in supplying quality active pharmaceutical agents as well as formulations to biopharmaceuticals intended for research and development. Everolimus CAS#: 159351-69-6 is one of the many active pharmaceutical agents supplied by LGM Pharma to its clients. The company strongly believes in supply consistency, drug safety and efficacy. It supports the tireless efforts of its clients in introducing innovative medical and pharmaceutical solutions to everyday problems that plague human life. Because of this noble cause, supplying superior product quality is of utmost importance to LGM Pharma and has never compromised on this stance nor it ever will.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service